Evaxion Biotech announces strategic milestones for 2025

Evaxion Biotech (EVAX) announces its strategic milestones for 2025 after having now achieved almost all the milestones set for 2024. The 2025 milestones reflect Evaxion’s high activity level, broad pipeline and strong external interest in potential partnerships around both our AI-Immunology platform and pipeline assets. As such, the milestones underscore our continued anticipated strategic progress. Evaxion’s overriding priorities are execution upon our business development strategy, continuation of the ongoing EVX-01 phase 2 trial, the ongoing strengthening of our AI-Immunology platform and further advancement of our research activities, including progressing our ERV-based precision vaccine concept towards clinical development. Finally, the focus is, of course, on advancing our existing partnerships, including bringing the MSD collaboration, entered in September 2024, to option exercise. AI-Immunology: Launch of automated lead vaccine candidate design module; H2. Business development and partnerships: At least two new agreements; 2025. EVX-01: All patients completed EVX-01 dosing; H1. EVX-01: Supplemental phase 2 biomarker and immunogenicity data; H1. EVX-01: Two-year phase 2 clinical efficacy readout; H2. Precision ERV cancer vaccines: Selection of lead vaccine candidate; H2. MSD vaccine collaboration: MSD option exercise, up to $10 million option exercise fee; H2. EVX-V1: Lead antigens selected for CMV vaccine candidate; H2 .Infectious diseases: Two new pipeline candidates; 1 in H1, 1 in H2.